On imaging, these tumours share common features with diffuse low grade astrocytomas, however they tend to present with contrast enhancement.
Anaplastic astrocytomas occur in adulthood with peak incidence between 40 and 50 years of age, which is older than low grade astrocytomas and younger than glioblastomas 1.
As is the case with most parenchymal brain tumours, patients typically present in one of three ways: seizures, focal neurological deficit or symptoms of increased intracranial pressure.
The key features present in anaplastic astrocytomas that are absent in low grade tumours are mitotic activity and cellular pleomorphism. Unlike glioblastomas, however, they do not demonstrate necrosis or vascular proliferation.
CT appearances are intermediate, appearing as regions of low attenuation with positive mass effect. Enhancement is variable.
Anaplastic astrocytomas appear similar to low grade astrocytomas but are more variable in appearance and a single tumour demonstrates more heterogeneity.
The key to distinguishing anaplastic astrocytomas from low grade tumours is the presence of enhancement which should be absent in the latter (although one should note that variants, especially gemistocytic astrocytomas, can demonstrate enhancement). The pattern of enhancement is very variable 1.
Unlike glioblastomas, anaplastic astrocytomas lack frank necrosis, and as such central non-enhancing fluid intensity regions should be absent 1.
- T1: hypointense compared to white matter
- T2: generally hyperintense but can be heterogeneous in cases with blood calcification
T1 C+ (Gd)
- very variable but usually at least some enhancement is present
- presence of ring enhancement suggests central necrosis and thus glioblastoma rather than anaplastic astrocytoma
- increased choline-to-creatine ratio
- NAA preserved or mildly depressed
- no significant lactate
- intermediate levels of Myo-inositol (lower than low grade, but higher than GBM) 2
- MR perfusion: elevated cerebral blood volume
Treatment and prognosis
Compared to glioblastomas, there are relatively few trials looking at treatment regimens for anaplastic astrocytoma 3. General principles are the same, however, with surgical resection when possible being the treatment of choice with or without subsequent radiotherapy and/or chemotherapy. This depends on the treating clinician's preference, the degree of resection, patient demographics and whether or not the tumour has recurred.
As is the case with everything about anaplastic astrocytomas, prognosis is also intermediate between low grade astrocytomas and glioblastomas. Typically patients succumb to their tumour in 2-3 years, often with transformation into a glioblastoma 4.
The differential, given the heterogeneous and variable appearance of these tumours is relatively wide, and includes:
- other astrocytomas
- often multiple
- located at grey white matter junction
- absent NAA, absent myo-inositol
- ring enhancement
- older age group
- subacute cerebral infarct
- gyriform enhancement
- vascular territory
- open ring enhancement
- 1. Atlas SW. Magnetic Resonance Imaging Of The Brain And Spine. Lippincott Williams & Wilkins. (2009) ISBN:078176985X. Read it at Google Books - Find it at Amazon
- 2. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol. 2000;21 (9): 1645-9. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 3. Principles and Practice of Stereotactic Radiosurgery. Springer. (2008) ISBN:0387710701. Read it at Google Books - Find it at Amazon
- 4. DeVita VT, Lawrence TS, Rosenberg SA. Devita, Hellman & Rosenberg's cancer [electronic resource]. Lippincott Williams & Wilkins. (2008) ISBN:0781772079. Read it at Google Books - Find it at Amazon
- WHO classification of CNS tumours
- WHO grading of CNS tumours
- VASARI MRI feature set
- diffuse astrocytoma grading
- grade I:
- grade II:
- grade III
- grade IV:
- glioblastoma vs cerebral metastasis
- radiation-induced gliomas
- gliomatosis cerebri (growth pattern)
- specific locations
- treatment response
- Stupp protocol
- glioma treatment response assessment in clinical trials
- multicentric glioblastoma
- multifocal glioblastoma
- prognostic genetic markers